Tuesday, April 08, 2008 8:36:34 AM
Tuesday April 8, 8:30 am ET
- Grant to Cover Formulation Work, Stability Characterization of Dry-Patch Vaccine -
GAITHERSBURG, Md., April 8, 2008 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI - News) today announced it will receive a cost-reimbursement grant for up to $943,856 from the U.S. Army Medical Research and Materiel Command (USAMRMC) to perform preclinical work on a patch-based version of the anthrax vaccine.
Under the 1-year grant, Iomai scientists will use vaccine antigen developed by UK-based Avecia Biologics Ltd., applying Iomai's technology in an effort to formulate a dry version of antigen that can be combined with an Iomai adjuvant on a needle-free patch. Iomai will then evaluate the stability of the patch to determine whether it can be stored and shipped at room temperature.
The current anthrax vaccine licensed in the United States is given as a six-shot regimen over an 18-month course and must be refrigerated, complicating stockpiling efforts. Government funding for a second-generation vaccine was discontinued after problems emerged with the stability of that vaccine.
"The military has a clear need for an effective anthrax vaccine that can be stockpiled and shipped at room temperature, and we believe that Iomai has the scientific know-how and the manufacturing ability to meet that need," said Stanley C. Erck, President and Chief Executive Officer of Iomai. "This grant further validates the Iomai approach of formulating vaccines and immunostimulants on stable dry patches, and our work under this grant will dovetail nicely with our ongoing clinical and preclinical programs."
The work on the Department of Defense grant will focus on Iomai's technology for drying proteins such as the anthrax vaccine so that they can be administered via a patch the size of an adhesive bandage. That technology is at the core of the company's vaccines for travelers' diarrhea and influenza as well as its immunostimulant adjuvant patches for pandemic influenza and seasonal flu in the elderly.
The information contained in this press release does not necessarily reflect the position or the policy of the U.S. Government, and no official endorsement should be inferred.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM